Andy Obermueller
Government-Driven Investing
Keith Fitz-Gerald
New China Trader
Marvin Appel
Systems & Forecasts
Jim Powell
Global Changes & Opportunities Report

Amgen (AMGN): Biotech value


Bookmark and Share

 "Amgen (NASDAQ: AMGN), the global biotechnology firm, is our latest 'stock of the month' selection," says value investor Charles Mizrahi. Here's the latest from Hidden Values Alert.

Advertisement
Banner

"The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology and inflammation.

"Its Aranesp is used for the treatment of anemia both in supportive cancer care and in nephrology. EPOGEN is used to treat anemia associated with chronic renal failure.

"Neulasta and NEUPOGEN selectively stimulate the production of neutrophils, one type of white blood cell that helps the body fight infections.

"Amgen generated more than $5.3 billion in free cash flow during the past twelve months. The company's balance sheet is strong; its current ratio (assets to liabilities) is 4:1. Amgen's net profit margin is currently 32.5%.

"In my view, AMGN is a well-run business, and a price of $49 or lower per share represents a very good value. If AMGN can grow earnings at only 8.5% per annum and maintain a P/E of 13, the stock will handsomely reward investors during the next five years."




News Flash

Geron (GERN)
Steve Christ, The Wealth Advisory

In a recent 15-page ruling, a U.S. judge ruled that using taxpayer dollars to fund embryonic stem cell research violates a 1996 law; but in the case of Geron Corp. (GERN), the company won’t be affected at all.


Read more...

 

Industrial trio: BWA, TEN, DXPE
Stephen Quickel, US Investment Report

Among our new stock are three industrials that expected to grow earnings by 30% a year: Borg Warner (BWA), Tenneco (TEN) and DXP Enterprises (DXPE).


Read more...


Banner
Banner
   

Bullion Monarch Mining (BULM)
Max Bowser, The Bowser Report

Bullion Monarch Mining (BULM) -- a holding in our "penny stock" portfolio -- recorded its best revenue year ever.


Read more...

 

Global X Lithium ETF (LIT)
Jim Trippon, ETF Profit Report

It’s rare that we would recommend an ETF that is as new as Global X Lithium (LIT), but with the market taking a tumble, we believe we’re getting good value on this newly-minted vehicle.


Read more...

 

Consumer Staples (XLP)
by Doug Fabian, Making Money Alert

The Consumer Staples Select Sector SPDR (XLP) is an ETF that tracks companies that have products that people need in both good and bad economic times.


Read more...

 

WisdomTree SmallCap Dividend (DES)
by Walter Frank, MoneyLetter

WisdomTree SmallCap Dividend (DES), which sports an attractive 4.3% yield, has been added to our fund coverage.


Read more...

 

Closed-end income favorites
by Harry Domash, Dividend Detective

The latest new positions in our closed-end fund portfolio are Guggenheim Emerging Opportunity (GOF) and First Trust/Aberdeen Emerging Opportunity (FEO).


Read more...

 

Quality trio: XOM, GOOG, JNJ
by Adam Sharp, contributing editor Wealth Daily

Buying defensive blue chips makes sense. Three of my favorites are ExxonMobil (XOM), Johnson and Johnson (JNJ) and Google (GOOG).


Read more...

 

Xcel Energy (XEL)
by Roger Conrad, The Utility Forecaster

In late 2002 Xcel Energy (XEL) was on the brink of Chapter 11; it has since come back, recently earning a credit upgrade from S&P to A- with an "excellent" risk profile.


Read more...

 

Virginia Mines (VGQ)
by Adrian Day, The Global Analyst

Virginia Mines (VGQ) remains one of a handful of my favorite companies; the company continues ongoing rationalization of its extensive mining property portfolio.


Read more...